Streetbeat News

Analyst Ratings

CHK

Truist Securities analyst Neal Dingmann has maintained a 'Buy' rating on Chesapeake Energy (NASDAQ:CHK) but lowered the price target from $102 to $100.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 2:35 pm

TSHA

Truist Securities analyst Joon Lee maintains a 'Buy' rating on Taysha Gene Therapies (NASDAQ:TSHA) and raises the price target from $2 to $6.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 2:32 pm

SBOW

Truist Securities analyst Neal Dingmann maintains a 'Buy' rating on SilverBow Resources (NYSE:SBOW) and raises the price target from $51 to $59.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 2:31 pm

WULF

Cantor Fitzgerald analyst Josh Siegler has reiterated an Overweight rating on TeraWulf (NASDAQ:WULF) and maintained a $4 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 2:30 pm

SCYX

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on SCYNEXIS (NASDAQ:SCYX) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 2:29 pm

FBIO

Cantor Fitzgerald analyst Jennifer Kim has reiterated an Overweight rating on Fortress Biotech (NASDAQ:FBIO) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 2:28 pm

SEEL

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Seelos Therapeutics (NASDAQ:SEEL) and maintained a $2 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 2:27 pm

RETA

Cantor Fitzgerald analyst Charles Duncan has reiterated a Neutral rating on Reata Pharmaceuticals (NASDAQ:RETA) and maintained a price target of $172.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 2:26 pm

AZYO

Cantor Fitzgerald analyst Brandon Folkes has reiterated an Overweight rating on Aziyo Biologics (NASDAQ:AZYO) and maintained a price target of $8.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 2:19 pm

TSHA

JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $4 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 2:17 pm